Drug
Motesanib diphosphate clinical trials
Also written AMG 706 and Motesanib.
- studies test it
- 17
- open now
- 0
- in phase 3
- 2
- first study started
- 2003
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2005 (5)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2004 | 2 |
| 2005 | 5 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 1 |
| 2012 | 1 |
| 2013 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 9
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 14 · Other 3
Amgen (13) · Eastern Cooperative Oncology Group (1) · Gynecologic Oncology Group (1) · Takeda (1) · Sidney Kimmel Cancer Center at Thomas Jefferson University (1)
Often tested with
Tested in the same studies.
Octreotide (1) · Sorafenib (1) · Trebananib (1) · Sunitinib (1) · Bevacizumab (1) · Ixabepilone (1) · Capecitabine (1)
Studies
Open first, then newest update. How each study uses motesanib diphosphate is read from its arms, and is right about nine times in ten.
Testing it · 17
- Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast CancerWithdrawnPhase 1/2Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01349088Written as Motesanib
- AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine TumorsCompletedPhase 2Eastern Cooperative Oncology GroupNCT00427349Written as AMG 706
- AMG 706 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedPhase 2Gynecologic Oncology GroupNCT00574951Written as motesanib diphosphate
- A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLCTerminatedPhase 2AmgenNCT00369070Written as AMG 706
- To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.CompletedPhase 1AmgenNCT00861419Written as AMG 706
- Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung CancerTerminatedPhase 3TakedaNCT02629848Written as Motesanib
- An Open Label Treatment Extension Study of AMG 706TerminatedPhase 2AmgenNCT00360867Written as AMG 706
- A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast CancerTerminatedPhase 2AmgenNCT00356681Written as AMG 706
- MONET1-MOtesanib NSCLC Efficacy and Tolerability StudyTerminatedPhase 3AmgenNCT00460317Written as AMG 706
- Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced CancerTerminatedPhase 1AmgenNCT00101907Written as AMG 706
- Evaluate the Efficacy of AMG 706 to Treat Advanced Gastrointestinal Stromal TumorsCompletedPhase 2AmgenNCT00254267Written as AMG 706
- A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid CancerCompletedPhase 2AmgenNCT00121628Written as AMG 706
- Study Evaluating AMG 706 in Subjects With Advanced Solid TumorsCompletedPhase 1AmgenNCT00093873Written as AMG 706
- Study of AMG 706 in Subjects With Advanced Gastrointestinal Stromal Tumors (GISTs)CompletedPhase 2AmgenNCT00089960Written as AMG 706
- Single Dose Study of [14C]-Labelled AMG 706 in Patients With Advanced Solid TumorsCompletedPhase 1AmgenNCT01386866Written as AMG 706
- Effect of Different Doses of AMG 706 on the Gallbladder in Advanced Solid TumorsCompletedPhase 1AmgenNCT00448786Written as AMG 706
- A Phase 1b, Open-label, Dose-finding Study of AMG 706 in Combination With Gemcitabine and Erlotinib to Treat Subjects With Solid TumorsCompletedPhase 1AmgenNCT01235416Written as AMG 706
Given in every arm · 3 — motesanib diphosphate is usual care beside what is tested
- Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 1/2AmgenNCT00094835Written as Motesanib diphosphate
- Phase1b to Evaluate Safety of AMG706 in Combination With Paclitaxel or Docetaxel for Breast CancerCompletedPhase 1AmgenNCT00322400Written as AMG 706
- Safety of AMG 706 Plus Panitumumab Plus Chemotherapy in the Treatment of Subjects With Metastatic Colorectal CancerCompletedPhase 1AmgenNCT00101894Written as AMG 706
Codes
What other systems call motesanib diphosphate · ClinicalTrials.gg INT000874
- MeSH (NLM) C000625785motesanib diphosphateConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) T6Q3060U91MOTESANIB DIPHOSPHATEConfirmed FDA, NLM, Wikidata
- Wikidata Q27289746motesanib diphosphateConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48374Motesanib DiphosphateOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625785 | motesanib diphosphate | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | T6Q3060U91 | MOTESANIB DIPHOSPHATE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27289746 | motesanib diphosphate | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48374 | Motesanib Diphosphate | One source FDA |
Also registered as motesanib (UNII U1JK633AYI).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.